Stop Oxy Abuse Act of 2013

Bill: 113-hr-1366
Sponsor: full_name: Rep. Lynch, Stephen F. [D-MA-8]
Introduced: 2013-03-21
Policy area: Health
Subjects: Drug safety, medical device, and laboratory regulation

Prescription drugs
Latest action: action_date: 2013-03-22
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2013-03-21
action_desc: Introduced in House
text: <p>Stop Oxy Abuse Act of 2013 - Directs the Commissioner of Food and Drugs (FDA), within 90 days, to take such actions as may be necessary to modify the approval of, and limit any subsequent approval of, any drug containing controlled-release oxycodone hychloride to use for the relief of severe-only pain instead of moderate-to-severe pain.</p>

tv_txt: I 113th CONGRESS 1st Session H. R. 1366 IN THE HOUSE OF REPRESENTATIVES March 21, 2013 Mr. Lynch (for himself, Mr. Fitzpatrick , Mr. Rogers of Kentucky , Mr. Rahall , Mr. Keating , Mr. Wolf , and Ms. Slaughter ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To direct the Commissioner of Food and Drugs to modify the approval of any drug containing controlled-release oxycodone hydrochloride to limit such approval to use for the relief of severe-only instead of moderate-to-severe pain, and for other purposes.

1. Short title This Act may be cited as the Stop Oxy Abuse Act of 2013 . 2. Limiting approval of drugs containing controlled-release oxycodone hydrochloride to use for relief of severe-only pain (a) In general Not later than 90 days after the date of the enactment of this Act, the Commissioner of Food and Drugs shall take such actions as may be necessary— (1) to modify the approval of any drug containing controlled-release oxycodone hydrochloride under section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ) to limit such approval to use for the relief of severe-only instead of moderate-to-severe pain; and (2) to limit any subsequent approval of a drug containing controlled-release oxycodone hydrochloride under such section to use for the relief of severe-only pain. (b) Applicability Any modification required by subsection (a)(1) shall apply to drugs introduced or delivered for introduction into interstate commerce on or after the date that is 180 days after the date of the enactment of this Act.